Abstract
We report a 19-year-old patient with systemic-onset juvenile idiopathic arthritis (JIA) who developed a mediastinal germinoma during treatment with infliximab. Although the cancer risk of infliximab is controversial, this agent may have accelerated the growth of the germinoma. We conclude that the indications for tumor necrosis factor (TNF) inhibitors should be strictly decided and that a nationwide cohort study is necessary to assess the risk of cancer in patients with JIA exposed to biologics.
MeSH terms
-
Antibodies, Monoclonal / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Antirheumatic Agents / therapeutic use*
-
Arthritis, Juvenile / complications
-
Arthritis, Juvenile / drug therapy*
-
Arthritis, Juvenile / pathology*
-
Combined Modality Therapy
-
Drug Substitution
-
Germinoma / complications
-
Germinoma / pathology*
-
Germinoma / therapy
-
Glucocorticoids / therapeutic use
-
Humans
-
Infliximab
-
Male
-
Mediastinal Neoplasms / complications
-
Mediastinal Neoplasms / pathology*
-
Mediastinal Neoplasms / therapy
-
Prednisolone / therapeutic use
-
Treatment Outcome
-
Young Adult
Substances
-
Antibodies, Monoclonal
-
Antirheumatic Agents
-
Glucocorticoids
-
Prednisolone
-
Infliximab